Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXL NASDAQ:MLTX NASDAQ:PHAR NASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$3.10-4.5%$3.68$2.61▼$13.99$286.81M1.241.38 million shs438,950 shsMLTXMoonLake Immunotherapeutics$18.29-2.9%$17.47$5.95▼$62.75$1.31B1.011.69 million shs325,523 shsPHARPharming Group$13.06+3.5%$16.13$8.69▼$21.34$921.94M0.0424,143 shs3,562 shsQUREuniQure$27.79+0.5%$16.94$8.73▼$71.50$1.77B0.872.85 million shs364,500 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+0.62%-2.41%+9.83%-18.18%-60.73%MLTXMoonLake Immunotherapeutics+10.43%+12.61%+4.90%+20.61%-51.03%PHARPharming Group-1.01%-24.33%-24.82%-20.64%+28.11%QUREuniQure-0.07%+44.49%+79.71%+11.86%+116.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$3.10-4.5%$3.68$2.61▼$13.99$286.81M1.241.38 million shs438,950 shsMLTXMoonLake Immunotherapeutics$18.29-2.9%$17.47$5.95▼$62.75$1.31B1.011.69 million shs325,523 shsPHARPharming Group$13.06+3.5%$16.13$8.69▼$21.34$921.94M0.0424,143 shs3,562 shsQUREuniQure$27.79+0.5%$16.94$8.73▼$71.50$1.77B0.872.85 million shs364,500 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+0.62%-2.41%+9.83%-18.18%-60.73%MLTXMoonLake Immunotherapeutics+10.43%+12.61%+4.90%+20.61%-51.03%PHARPharming Group-1.01%-24.33%-24.82%-20.64%+28.11%QUREuniQure-0.07%+44.49%+79.71%+11.86%+116.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 2.40Hold$21.33589.28% UpsideMLTXMoonLake Immunotherapeutics 2.38Hold$23.8530.41% UpsidePHARPharming Group 2.60Moderate Buy$38.33193.43% UpsideQUREuniQure 2.53Moderate Buy$42.8354.12% UpsideCurrent Analyst Ratings BreakdownLatest AVXL, QURE, MLTX, and PHAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026MLTXMoonLake Immunotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $30.005/11/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.005/6/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $50.005/5/2026QUREuniQure Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$28.005/4/2026AVXLAnavex Life Sciences Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.004/30/2026QUREuniQure Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $37.004/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/22/2026AVXLAnavex Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026QUREuniQure The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$9.00 ➝ $10.004/13/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/10/2026PHARPharming Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.10 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/APHARPharming Group$376.13M2.45$0.20 per share64.72$3.95 per share3.31QUREuniQure$16.10M108.87N/AN/A$3.19 per share8.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$46.38M-$0.46N/AN/AN/AN/A-38.76%-35.01%N/AMLTXMoonLake Immunotherapeutics-$227.32M-$3.52N/AN/AN/AN/A-66.56%-50.23%N/APHARPharming Group$2.85M$0.1681.6029.69N/A3.30%4.64%2.55%7/30/2026 (Estimated)QUREuniQure-$198.97M-$3.48N/AN/AN/A-1,154.42%-145.81%-27.15%N/ALatest AVXL, QURE, MLTX, and PHAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/A5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 million3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 million3/3/2026Q4 2025QUREuniQure-$0.93-$0.56+$0.37-$0.56$4.84 million$5.57 million2/25/2026Q4 2025MLTXMoonLake Immunotherapeutics-$0.92-$0.92N/A-$0.92N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A20.8720.87MLTXMoonLake Immunotherapeutics0.249.279.27PHARPharming Group0.352.632.06QUREuniQure0.3310.4010.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%MLTXMoonLake Immunotherapeutics93.85%PHARPharming Group0.03%QUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.00%MLTXMoonLake Immunotherapeutics12.05%PHARPharming Group2.07%QUREuniQure4.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4092.67 million82.48 millionOptionableMLTXMoonLake Immunotherapeutics271.73 million63.09 millionOptionablePHARPharming Group28070.62 million69.16 millionNot OptionableQUREuniQure50063.07 million60.05 millionOptionableAVXL, QURE, MLTX, and PHAR HeadlinesRecent News About These CompaniesNan Fung Trinity HK Ltd. Purchases New Holdings in uniQure N.V. $QUREMay 10 at 6:32 AM | marketbeat.comuniQure N.V. (NASDAQ:QURE) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMay 8, 2026 | finance.yahoo.comHC Wainwright Issues Optimistic Outlook for uniQure EarningsMay 8, 2026 | marketbeat.comFDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?May 7, 2026 | fiercepharma.comFWhat is HC Wainwright's Forecast for uniQure Q1 Earnings?May 7, 2026 | marketbeat.comUniQure plans UK AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029May 7, 2026 | msn.comUniQure plans U.K. AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029May 5, 2026 | seekingalpha.comuniQure Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comuniQure N.V. (QURE) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comuniQure (NASDAQ:QURE) Issues Quarterly Earnings ResultsMay 5, 2026 | marketbeat.comuniQure (QURE) Reports Q1 Loss, Misses Revenue EstimatesMay 5, 2026 | zacks.comUniQure: Q1 Earnings SnapshotMay 5, 2026 | chron.comuniQure Announces First Quarter 2026 Financial Results and Provides Recent Company UpdatesMay 5, 2026 | globenewswire.comHow The uniQure (QURE) Investment Story Is Shifting With AMT-130 And Regulatory UncertaintyMay 4, 2026 | finance.yahoo.comuniQure (NASDAQ:QURE) Shares Up 6.3% - Still a Buy?May 4, 2026 | marketbeat.comuniQure N.V. (NASDAQ:QURE) Receives $42.83 Consensus Price Target from AnalystsMay 4, 2026 | americanbankingnews.comuniQure’s AMT-130 Regulatory Progress Sharpens Huntington’s Disease Investment CaseMay 3, 2026 | finance.yahoo.comJennison Associates LLC Boosts Stake in uniQure N.V. $QUREMay 2, 2026 | marketbeat.comuniQure (QURE) Expected to Announce Quarterly Earnings on TuesdayMay 1, 2026 | americanbankingnews.comuniQure (QURE) Projected to Post Earnings on TuesdayMay 1, 2026 | marketbeat.comUniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrelApril 30, 2026 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVXL, QURE, MLTX, and PHAR Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$3.10 -0.15 (-4.48%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.MoonLake Immunotherapeutics NASDAQ:MLTX$18.29 -0.55 (-2.94%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Pharming Group NASDAQ:PHAR$13.06 +0.44 (+3.52%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.uniQure NASDAQ:QURE$27.79 +0.15 (+0.55%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
